Increased expression of squamous cell carcinoma antigen 1 and 2 in mycosis fungoides and Sezary syndrome" trans "Increased expression of squamous cell carcinoma antigen 1 and 2 in mycosis fungoides and Sezary syndrome.
Differences in Thymus and Activation-Regulated Chemokine and Squamous Cell Carcinoma Antigen 2 Levels in Food Protein-Induced Enterocolitis Syndrome and Atopic Dermatitis.
Evaluation of squamous cell carcinoma antigen 1 expression in oral squamous cell carcinoma (tumor cells and peritumoral T-lymphocytes) and verrucous carcinoma and comparison with normal oral mucosa.
Studied association of progastrin-releasing peptide (proGRP) neuron specific enolase (NSE) chromogranin a (CgA) and squamous cell cancer antigen (SCCA1) in pulmonary neuroendocrine tumor (PNET) and non-small-cell lung carcinoma (NSCLC). Results showed ProGRP can distinguish PNET patients from NSCLC patients and with adjusted NSE values it can differentiate the PNET group from the benign disease group.
serum SCCA can not only be used in diagnosis and prognosis of squamous cell carcinomas but also as biomarkers for uremia azotemia diabetic nephropathy and nephritic syndrome.
Results provide evidence that SCCA1 overexpression is associated with poor prognosis in esophageal cancer patients. which is due to reduced tumor chemosensitivity as well as intratumoral immunity impairment possibly mediated by the induction of the PD-L1 immune checkpoint regulator.
Fifty-two of 96 cases (54%) showed evaluated serum SCC antigen levels above the upper limit. The serum SCCA2 level was significantly higher in the head and neck SCC patients than in control group whereas there were no significant differences in the serum SCCA1 level between head and neck SCC patients and control group.
The combination of SCCA-IgM with common clinical data shows promising diagnostic performance for the detection of Non-alcoholic steato-hepatitis in hepatitis C virus patients
Findings point to potential interest of squamous cell carcinoma antigen SERPINB3/B4 for the stratification of head and neck squamous cell carcinoma (HNSCC) patients in the therapeutic context.
Results provide the first evidence that failure of serum SCCA to fall into the normal range by the fourth week of definitive radiotherapy is associated with significantly increased risk of recurrence and death.
While novel diagnostic tumour markers are urgently needed the examined potential tumour markers with the exception of PIVKAII seem to be inadequate for diagnosing HCC in ALC
Serum SCCA2 levels reflected disease severity and clinical type of atopic dermatitis. Serum SCCA2 may thus be a relevant biomarker for atopic dermatitis.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.